B7-H3CART

DRUG2 trials

Sponsors

Stanford University

Conditions

Brain and Nervous SystemOvarian Cancer

Phase 1

B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme

RecruitingNCT05474378

Stanford UniversityBrain and Nervous System

Start: 2022-07-12End: 2027-02-01Target: 39Updated: 2026-09-15

Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant Ovarian Tumors

RecruitingNCT06646627

Stanford UniversityOvarian Cancer

Start: 2024-11-11End: 2027-01-01Target: 48Updated: 2026-09-10

Related Papers

EPCO-45. SINGLE-CELL LANDSCAPE OF B7H3-CAR T THERAPY IN GLIOMA: MECHANISMS OF RESISTANCE AND SIGNATURES OF LONG-TERM RESPONSE

Neuro-Oncology2025-11-01

BIOM-107. EVALUATION OF B7-H3 IMMUNOHISTOCHEMISTRY IN HIGH-GRADE GLIOMAS FOR CHIMERIC ANTIGEN RECEPTOR T-CELL PREDICTIVE TESTING

Neuro-Oncology2025-11-01

A phase 1 study of B7H3 CAR-T cells administered intracranially in recurrent glioblastoma.

Journal of Clinical Oncology2025-05-283 citations